"myTomorrows partners with Pancreatic Cancer Europe on clinical trials"

myTomorrows and Pancreatic Cancer Europe have joined forces to improve access to clinical trials for pancreatic cancer patients. This partnership aims to expand treatment options and support better outcomes by connecting patients with innovative therapies. The collaboration focuses on bridging the gap between patients and clinical research, ensuring those with pancreatic cancer have more opportunities to participate in potentially life-saving trials.

The partnership will enhance care for pancreatic cancer patients.

myTomorrows, a global health technology company that connects patients with all available treatment options, has announced a new collaboration with Pancreatic Cancer Europe, a multi-stakeholder platform uniting experts across Europe to improve pancreatic cancer care.

Through this collaboration, Pancreatic Cancer Europe (PCE) will leverage myTomorrows' database of active clinical trials to provide patients, caregivers, and healthcare professionals (HCPs) with current and accessible information about pre-approval treatments that may be suitable for them.

This partnership between the European patient advocacy group and myTomorrows will broaden access to all potential treatment options for patients with various life-threatening conditions. For pancreatic cancer patients and HCPs, it will simplify the process of identifying and understanding available clinical trial options.

Pancreatic cancer ranks as the fourth leading cause of cancer deaths, with a life expectancy of just 6-12 months at diagnosis and a five-year survival rate of only 10%. The challenges of pancreatic cancer include low public awareness, late diagnosis, resistance to chemotherapy and radiation, poor survival rates, and limited treatment options. Therefore, it is vital for patients to be accurately and thoroughly informed about their treatment options, especially clinical trials, which are often hard to locate, comprehend, and navigate.

For questions or comments write to writers@bostonbrandmedia.com

Source: pharmatimes‍